TIDES is the only event with full coverage of discovery, development and manufacturing of oligonucleotide and peptide therapeutics. Sessions cover CMC manufacturing of peptide and oligonucleotide-based therapeutics in an in-depth manner, together with complete coverage of drug discovery and development.
This conference is the industry's most innovative and comprehensive conference for sharing best practices and new ideas to accelerate the discovery, engineering and development of alternative scaffolds and novel protein therapeutics to create differentiated drugs.
This conference focuses on discovery, design, development and CMC manufacturing issues of antibody-drug conjugates and many other types of bioconjugates, in order to facilitate information sharing and help companies move their programs forward.
For more than 100 years, BD Biosciences - Advanced Bioprocessing has helped biopharmaceutical companies enhance complex media formulations with unique supplements and feeds to improve yield and reduce variability. Our products have been used in batch, fed-batch and perfusion processes across a number of applications to improve protein production and quality. (By invitation only)
IBC's Antibody Engineering & Therapeutics China meeting is the leading forum in Asia for bringing together leading scientists and innovators from around the world to discuss novel strategies for antibody, protein and biotherapeutic discovery and development.
BioProcess International China conference is the region's foremost event on bioprocessing and biomanufacturing. It provides you with the most timely information, tools, strategies and techniques that you need to ensure optimal development, from upstream to scale-up to commercialization.
IBC's Cell Therapy Bioprocessing conference has built a reputation of providing a first-rate faculty of participants, who collectively share perspectives and lessons learned from detailed case studies to help you overcome the challenges, develop the strategies and implement the technologies to propel this field towards commercial sustainability.
Providing insights on the latest advances in cancer immunotherapies, IBC's Immuno-Oncology meeting will focus on overcoming challenges with discovery, development, approval, and product launch. Discussions will cover methods to improve efficacy, potency, and viability of potential therapeutic candidates.